



INTRAVENOUS INFUSIONS PLC

MANUFACTURERS OF PHARMACEUTICAL PRODUCTS

"Saving lives since 1969"

Intravenous Infusions PLC
Unaudited Financial Statements for the
Six Months Ended 30 June 2022



INTRAVENOUS INFUSIONS PLC
 MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
"Saving lives since 1969"

KEY FINANCIAL HIGHLIGHTS

	30 JUNE 2022 UNAUDITED GH¢	30 JUNE 2021 UNAUDITED GH¢	% CHANGE YOY
Revenue	9,915,099	11,527,052	-14%
Gross Profit	4,327,780	6,541,018	-34%
Finance Costs	104,000	170,822	-39%
Operating Profit	(1,088,718)	2,373,702	-146%
Net Profit/(Loss) before tax	(1,192,718)	2,202,880	-154%
Net Shareholders' funds	17,095,160	19,729,897	-13.0%
Cash and cash Equivalent	322,575	61,509	424%
Trade and other receivables	15,814,678	16,280,912	2.86%

UNAUDITED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	30 JUNE 2022 UNAUDITED GH¢	30 JUNE 2021 UNAUDITED GH¢	% CHANGE YOY
Revenue	9,915,099	11,527,052	-14%
Cost of operations	5,587,319	(4,986,034)	12%
Gross profit	4,327,780	6,541,018	-34%
Other income	6,823	18,418	-63%
Operating and other expenses	(5,150,850)	(4,185,734)	-23%
Profit before finance cost and tax	(1,088,718)	2,373,702	-146%
Finance cost	(104,000)	(170,822)	-39%
Profit before tax	(1,192,718)	2,202,880	-154%
Income tax expense	0	(413,040)	-100%
Profit for the period	(1,192,718)	1,789,840	-167%
Earnings per share	-0.0043	0.0065	-166%



INTRAVENOUS INFUSIONS PLC
 MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
"Saving lives since 1969"

UNAUDITED STATEMENT OF FINANCIAL POSITION

	30 JUNE 2022 UNAUDITED GH¢	30 JUNE 2021 UNAUDITED GH¢	% CHANGE YOY
ASSETS			
Non-current assets			
Property, plant and equipment	20,162,744	14,984,439	35%
Current assets			
Inventory	7,379,292	5,738,615	29%
Trade and other receivables	15,814,678	16,852,857	-6%
Cash	322,575	61,509	424%
Total current assets	23,516,545	22,652,981	4%
Total assets	43,679,289	37,637,420	16%
Equity			
Stated capital	11,626,451	11,626,451	0%
Retained earnings	3,365,589	6,000,326	-44%
Capital surplus	2,103,120	2,103,120	0%
Total equity	17,095,160	19,729,897	-13%
Non-Current Liability			
Deferred Tax liability	414,537	424,590	-2%
Medium term loan	12,916,912	10,305,780	25%
Total Non- current liability	13,331,449	10,730,370	24%
Current liabilities			
Borrowings	1,730,076	2,228,467	-22%
Trade and other payables	11,282,148	4,801,257	186%
Current tax	240,455	147,429	63%
Employee Benefit obligation	0	0	0%
Total Current Liabilities	13,252,679	7,177,153	85%
Total Liabilities	26,584,129	17,907,523	48%
Total Liabilities and Equity	43,679,289	37,637,420	16%



UNAUDITED STATEMENT OF CHANGES IN EQUITY

	Stated capital	Deposit for shares	Income surplus	Capital surplus	Total
Balance at 1 st Jan 2022	11,626,451		4,558,307	2,103,120	18,287,878
issue of shares(net)					
Profit/(Loss) for the period					
Dividend paid					
Transfer from profit and loss			(1,192,718)		(1,192,718)
At 30 th June 2022	11,626,451		3,365,589	2,103,120	17,095,160

UNAUDITED STATEMENT OF CASH FLOWS

	30 JUNE 2022 UNAUDITED GH¢	30 JUNE 2021 UNAUDITED GH¢
Operating activities		
Profit before tax	(1,192,718)	2,202,880
Adjustments for non-cash income and expenses:		
Net employee obligation		
Depreciation of property, plant and equipment	272,470	356,106
Cash flow included in operating activities	(920,248)	2,558,985
Changes in operating assets and liabilities		
Decrease/increase in trade and other receivables	1,578,088	(463,461)
Increase/decrease in trade payables	(93,410)	(701,619)
Increase/decrease in inventory	275,139	(324,141)
Cash flow from operating activities	839,571	1,069,764
Tax paid	(21,291)	(200,976)
Net cash from operating activities	818,280	868,788
Cash flows from investing activities		
Purchases of equipment	(24,000)	(2,411,631)
Net cash used in investing activities	(24,000)	(2,411,631)
Cash flows from financing activities		
Dividend paid		
Increase in borrowings	(1,278,415)	(604,582)
Net cash used in financing activities	(1,278,415)	(604,582)



INTRAVENOUS INFUSIONS PLC
MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
"Saving lives since 1969"

Net (increase/decrease) in cash and cash equivalents	484,135	(938,261)
Cash and cash equivalents at beginning of year	806,710	999,770
Cash and cash equivalents at 30 June 2022	322,575	61,509

Moukhtar Soalihi
(Managing Director)

Eugenia Bulley
(General Manager, Finance and Administration)